We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
Read MoreHide Full Article
Key Takeaways
{\"0\":\"HIMS reached 2.4 million subscribers in Q1 2025, with over 1.4 million using personalized health solutions.\",\"1\":\"A new CTO hire and $870 million in funding will boost HIMS\' AI strategy and global expansion efforts.\",\"2\":\"HIMS is integrating pharmacy and diagnostics to control fulfillment and care quality at scale.\"}
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and scalability. Its model integrates telehealth consultations, electronic medical records, cloud-based pharmacy fulfillment and artificial intelligence (AI)-driven care routing — creating a seamless end-to-end user experience across conditions like mental health, dermatology, sexual wellness and weight management. HIMS’ subscription-based approach reached 2.4 million subscribers in first-quarter 2025, with over 1.4 million using personalized solutions, reflecting strong demand for tech-enabled care.
Central to Hims & Hers’ strategy is its expanding investment in AI. The recent appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal move toward scaling intelligent, individualized care. Elshenawy brings over two decades of experience in AI, robotics and cloud infrastructure, and is tasked with enhancing diagnostics, automation and platform personalization. These efforts are supported by an $870 million upsized convertible notes offering, with proceeds earmarked for AI innovation and global expansion.
Hims & Hers is also vertically integrating its operations through acquisitions in pharmacy and diagnostics, enabling greater control over fulfillment and care quality. Tools like MedMatch use data to route patients to the right care pathways, while new AI applications aim to automate and refine diagnosis and treatment recommendations. By blending direct-to-consumer infrastructure with advanced technology, Hims & Hers is enhancing healthcare delivery for millions — offering a scalable model that delivers high-quality, personalized care with efficiency.
LFMD & DOCS’ Digital-First Transformation
LifeMD, Inc. (LFMD - Free Report) has rapidly evolved into a comprehensive digital-first healthcare platform offering vertically integrated telehealth solutions. With LifeMD's nationwide physician network, proprietary electronic medical records and in-house pharmacy operations, it delivers personalized care at scale. LFMD supports recurring subscription models across multiple specialties, including weight management and primary care. LifeMD’s tech-enabled ecosystem enhances clinical access, operational efficiency and long-term subscriber value through continuous innovation.
Doximity, Inc. (DOCS - Free Report) continues to redefine physician engagement through its digital-first strategy, offering HIPAA-compliant telehealth tools and AI-powered workflow enhancements. Doximity enables doctors to connect, consult and collaborate seamlessly within its professional network. DOCS’ platform integrates secure messaging, eFax and personalized newsfeeds, reflecting Doximity’s mission to streamline clinical operations and empower providers with intelligent, scalable solutions.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 171% year to date, outperforming the industry’s growth of 10.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 5.6X is lower than the industry’s average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 177.8% improvement from 2024.
Image: Bigstock
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and scalability. Its model integrates telehealth consultations, electronic medical records, cloud-based pharmacy fulfillment and artificial intelligence (AI)-driven care routing — creating a seamless end-to-end user experience across conditions like mental health, dermatology, sexual wellness and weight management. HIMS’ subscription-based approach reached 2.4 million subscribers in first-quarter 2025, with over 1.4 million using personalized solutions, reflecting strong demand for tech-enabled care.
Central to Hims & Hers’ strategy is its expanding investment in AI. The recent appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal move toward scaling intelligent, individualized care. Elshenawy brings over two decades of experience in AI, robotics and cloud infrastructure, and is tasked with enhancing diagnostics, automation and platform personalization. These efforts are supported by an $870 million upsized convertible notes offering, with proceeds earmarked for AI innovation and global expansion.
Hims & Hers is also vertically integrating its operations through acquisitions in pharmacy and diagnostics, enabling greater control over fulfillment and care quality. Tools like MedMatch use data to route patients to the right care pathways, while new AI applications aim to automate and refine diagnosis and treatment recommendations. By blending direct-to-consumer infrastructure with advanced technology, Hims & Hers is enhancing healthcare delivery for millions — offering a scalable model that delivers high-quality, personalized care with efficiency.
LFMD & DOCS’ Digital-First Transformation
LifeMD, Inc. (LFMD - Free Report) has rapidly evolved into a comprehensive digital-first healthcare platform offering vertically integrated telehealth solutions. With LifeMD's nationwide physician network, proprietary electronic medical records and in-house pharmacy operations, it delivers personalized care at scale. LFMD supports recurring subscription models across multiple specialties, including weight management and primary care. LifeMD’s tech-enabled ecosystem enhances clinical access, operational efficiency and long-term subscriber value through continuous innovation.
Doximity, Inc. (DOCS - Free Report) continues to redefine physician engagement through its digital-first strategy, offering HIPAA-compliant telehealth tools and AI-powered workflow enhancements. Doximity enables doctors to connect, consult and collaborate seamlessly within its professional network. DOCS’ platform integrates secure messaging, eFax and personalized newsfeeds, reflecting Doximity’s mission to streamline clinical operations and empower providers with intelligent, scalable solutions.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 171% year to date, outperforming the industry’s growth of 10.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 5.6X is lower than the industry’s average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 177.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.